Welcome to our dedicated page for ViewRay news (Ticker: VRAY), a resource for investors and traders seeking the latest updates and insights on ViewRay stock.
ViewRay, Inc. (Nasdaq: VRAY) is a trailblazer in the field of MRI-guided adaptive radiotherapy. The company designs, manufactures, and markets the MRIdian® radiation therapy system, an innovative solution aimed at addressing the key limitations of conventional external-beam radiation therapy technologies. Using cutting-edge MRI-based technology, the MRIdian system provides real-time imaging that precisely distinguishes the targeted tumor from surrounding soft tissue and critical organs during radiation treatment.
One of the standout features of the MRIdian system is its capability to record the level of radiation exposure the tumor receives and adapt the treatment prescription as needed. This adaptive approach enhances the safety and efficacy of radiation therapy, which ViewRay believes will lead to better patient outcomes.
ViewRay has established itself as a visionary in the medical field, dedicated to providing doctors with advanced tools to improve cancer treatment through radiation therapy. The company prides itself on its entrepreneurial spirit and unwavering commitment to innovation and excellence.
Among its recent achievements, ViewRay announced that the VA Oklahoma City Healthcare System has selected the MRIdian system to expand its radiation therapy services. This marks the first cancer center in Oklahoma to offer Veterans access to MRIdian's advanced MRI-guided radiation therapy. The system will enable precision treatment for various cancers, including pancreas, prostate, lung, liver, breast, and oligometastatic disease.
The Veterans Health Administration, the largest integrated healthcare system in America, is actively incorporating MRIdian technology across multiple VA medical centers. This expansion highlights the growing recognition of MRIdian's short-course non-invasive therapy, which promises fewer side effects and improved quality of life for patients.
To date, over 31,000 patients worldwide have been treated using MRIdian systems, with 62 installations in hospitals across the globe. These systems are employed to treat a diverse range of solid tumors and are subjects of numerous ongoing research studies. The MRIdian system has been featured in hundreds of peer-reviewed publications and scientific presentations, underscoring its clinical significance and impact.
For a list of treatment centers utilizing MRIdian technology, visit ViewRay's website.
ViewRay, Inc. (NASDAQ: VRAY) announced it will present at the Stifel 2022 Healthcare Conference. The presentation will feature CEO Scott Drake and CFO Zach Stassen in a fireside chat scheduled for 2:25 p.m. ET on November 15, 2022. An audio webcast will be available on the investor relations section of ViewRay's website, with a replay accessible for 7 days post-presentation. ViewRay designs and markets the MRIdian MRI-Guided Radiation Therapy System, which addresses unique challenges in radiation oncology.
ViewRay, Inc. (Nasdaq: VRAY) announced its Q3 2022 financial results, showing revenue of approximately $26.5 million, up from $19.2 million in Q3 2021. The company received eight new MRIdian system orders totaling $47.5 million, increasing total backlog to $370.5 million. Despite revenue growth, net loss was $26.1 million, slightly improving from $25.3 million a year earlier. ViewRay raised its revenue guidance for 2022 to between $94 million and $104 million and revised cash usage guidance to $78 million to $92 million.
ViewRay, Inc. (NASDAQ: VRAY) presented final results from its phase III MIRAGE trial at the ASTRO 2022 conference. The study compared MRIdian MRI-guided stereotactic body radiation therapy (SBRT) to CT-guided SBRT in localized prostate cancer. MRI-guidance showed a significant reduction in acute grade ≥2 genitourinary toxicity (24.4% vs. 43.4%) and gastrointestinal toxicity (0.0% vs. 10.5%). Patient-reported outcomes also favored MRI guidance, with fewer urinary and bowel symptoms. ViewRay aims to enhance radiation treatment safety and efficacy with MRIdian technology.
ViewRay, Inc. (NASDAQ: VRAY) announced the successful primary outcome from its Phase II SMART Pancreas study, achieving zero incidences of grade 3+ gastrointestinal toxicity while treating 136 pancreatic cancer patients. The study utilized the MRIdian SMART system, indicating potential for enhanced patient outcomes with ablative radiation doses. Preliminary results suggest a 93.9% one-year overall survival rate from diagnosis and 82.9% local control. The findings will be presented at the ASTRO Annual Meeting on October 25, 2022, by Dr. Parag Parikh, the principal investigator.
ViewRay, Inc. (NASDAQ: VRAY) will showcase its MRIdian® MRI-Guided Radiation Therapy System at the 64th ASTRO Annual Meeting from October 23-26, 2022. Key presentations include results from the SMART Pancreas study and the MIRAGE prostate trial, focusing on the benefits of MR-guided radiation therapy for advanced cancers. The new MRIdian A3i features improved workflow capabilities and real-time tracking for enhanced treatment precision. With over 25,000 patients treated, MRIdian's clinical experiences and innovations position it as a leader in adaptive radiation therapy.
ViewRay, Inc. (NASDAQ: VRAY) announced the initiation of a Phase III trial, LAP-ABLATE, aimed at comparing the effectiveness of its MRIdian SMART, combined with chemotherapy, against standard chemotherapy alone in locally advanced pancreatic cancer patients. The trial is set to enroll 267 participants and seeks to improve overall survival rates. The MRIdian technology enables precise radiation delivery while minimizing damage to surrounding tissues, addressing limitations of traditional methods. Previous studies have shown promising results, indicating a potential breakthrough in treatment.
ViewRay, Inc. (NASDAQ: VRAY) will release its third quarter 2022 financial results on November 1, 2022, at 5:00 p.m. ET. A conference call will follow to discuss these results, and interested participants can join by registering via the provided link. A live webcast will also be accessible on ViewRay's investor relations page, with a replay available afterward. ViewRay specializes in designing and manufacturing the MRIdian MR-Guided Radiation Therapy System, aimed at improving workflows in advanced radiation oncology.
ViewRay, Inc. (NASDAQ: VRAY) announces that SUNY Upstate Cancer Center in Syracuse, New York, will be the first in Upstate New York to utilize the MRIdian MRI-Guided Radiation Therapy System. This advanced therapy will be available for various cancers, including pancreas, prostate, and breast. The MRIdian system enhances treatment precision through diagnostic-quality MRI images, allowing real-time tracking of target tumors while minimizing radiation exposure to healthy tissue. Over 25,000 patients have been treated with MRIdian, which is installed in 54 hospitals globally.
ViewRay, Inc. (NASDAQ: VRAY) announces that San Pietro Fatebenefratelli Hospital in Rome has treated its 1,000th patient using the MRIdian MRI-guided radiation therapy system. This milestone was achieved in under three years, showcasing the system's efficiency for complex tumor treatments. The hospital has performed over 10,000 treatments, with 75% utilizing stereotactic body radiation therapy. The MRIdian system allows for precise targeting of tumors while minimizing damage to healthy tissue, reflecting its clinical value. Currently, over 25,000 patients have been treated with MRIdian worldwide.
ViewRay announced plans for an Investor Day on November 17, 2022, at 8:00 a.m. Eastern Time in New York City. The event will include presentations from the leadership team detailing business progress and future initiatives. A webcast will be available for those who cannot attend in person, and registration can be completed via the ViewRay website.
ViewRay, listed on NASDAQ as VRAY, specializes in the design and manufacturing of the MRIdian MR-Guided Radiation Therapy System, addressing unique challenges in radiation oncology.
FAQ
What does ViewRay, Inc. specialize in?
What is the MRIdian® system?
What recent achievement has ViewRay announced?
How many patients have been treated with the MRIdian system?
How many MRIdian systems are currently installed worldwide?
What types of cancer can be treated with MRIdian?
Why is MRIdian considered advanced in radiation therapy?
What are some common side effects of radiation therapy with MRIdian?
Is MRIdian suitable for all patients?
Where can I find more information about MRIdian treatment centers?
